|
Jul 1
|
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
|
|
Jun 30
|
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
|
|
Jun 24
|
Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target
|
|
Jun 23
|
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
|
|
Jun 20
|
3 Reasons We Love Natera (NTRA)
|
|
Jun 19
|
High Growth US Tech Stocks To Watch In June 2025
|
|
Jun 10
|
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
|
|
May 27
|
3 Mid-Cap Stocks Worth Your Attention
|
|
May 22
|
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
|
|
May 21
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
May 21
|
3 Stocks That May Be Trading Below Their Estimated Value
|
|
Apr 17
|
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
|
|
Apr 16
|
3 Top Stocks Estimated To Trade At Up To 48.4% Below Intrinsic Value
|
|
Apr 15
|
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
|
|
Apr 14
|
High Growth Tech Stocks In US With Potential For Expansion
|
|
Apr 14
|
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
|
|
Apr 12
|
Natera (NasdaqGS:NTRA) Climbs 11% in One Week
|
|
Apr 10
|
When Will Natera, Inc. (NASDAQ:NTRA) Turn A Profit?
|
|
Mar 14
|
Natera And 2 Other Stocks That May Be Trading Below Their Estimated Value
|
|
Mar 14
|
Exploring Three High Growth Tech Stocks In The US Market
|